跳至主要内容
临床试验/NCT06504849
NCT06504849招募中不适用

Instant Message-delivered Personalised Lifestyle Modification Intervention for Pre-hypertension Management Among Community Dwelling Adults: a Randomised Controlled Trial

The University of Hong Kong1 个研究点 分布在 1 个国家目标入组 256 人开始时间: 2024年5月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
256
试验地点
1
主要终点
24hr-systolic and diastolic BP

研究概览

简要总结

To assess the effectiveness of instant message-delivered personalised lifestyle modification (LSM) intervention for pre-hypertension (pre-HTN) management among community dwelling Chinese adults.

详细描述

Systolic blood pressure (BP) of 120-139 or diastolic BP 80-89mmHg were previously described as 'high normal' or 'above-optimal', but have been re-defined as pre-hypertention (HTN) in the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure(JNC-7) in order to raise awareness regarding the risks of elevated BP and to emphasise healthcare professionals' roles in managing elevated blood pressures as part of primary HTN prevention. Prevalence of pre-HTN is significant, specifically reported as 36.4% of adults in a large-scale population study conducted in mainland China. Furthermore, evidence has shown that the incidence of clinical HTN over 4 years in people with pre-HTN is twice that of people with normal BP, of which approximately 17% had accelerated progression to more advanced stages of HTN. The data highlight that a significant proportion of populations at risk of developing HTN if pre-HTN remains undetected and unmanaged, and also the importance of screening for pre-HTN to initiate management and mitigate the risks associated with HTN.

Lifestyle modification (LSM) is the primary intervention for people with pre-HTN as they play a significant role in lowering BP without the use of pharmacological treatments. Both LSM interventions and pharmacological treatments have been recommended for people with HTN in clinical and public health guidelines. Ecological momentary intervention (EMI) is defined as a health intervention delivered though the mobile device's messaging functions, particularly instant messaging.In existing randomised controlled trials (RCTs), EMI also showed efficacy on LSM, including smoking cessation, diet control, psychological well-being, and weight loss. EMI can therefore serve as an important 'platform' to deliver the LSM intervention in a personalised, real-time and in-situ format.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
Double (Participant, Investigator)

入排标准

性别
All
接受健康志愿者

入选标准

  • Systolic BP 120-139 or diastolic BP 80-89mmHg. The BP screening procedures and requirements (i.e., office BP measurement and ABPM) will strictly follow the International Society of Hypertension's Global Hypertension Practice Guidelines;
  • Aged ≥18 years;
  • Able to read and communicate in Chinese; and
  • Able to use mobile phone instant messaging function.

排除标准

  • Ever diagnosis of HTN;
  • Ever diagnosis of cardiovascular diseases (CVDs);
  • Pregnant or <3-month post-partum;
  • Current diagnosis of psychiatric disease or currently taking a psychotropic drug; and
  • Currently participating in any type of BP reduction intervention.

结局指标

主要结局

24hr-systolic and diastolic BP

时间窗: 6 months

The BP will be measured by 24hr-ambulatory BP monitoring.

次要结局

  • Body Mass Index (BMI)(6 months)
  • Salt-intake literacy (Chinese Health Literacy Scale for Low Salt Consumption - Hong Kong, CHLSALT-HK)(6 months)
  • DASH diet adherence (Self-reported quesionnaire)(6 months)
  • Physical activity (International Physical Activity Questionnaire - Short Form, IPAQ-SF)(6 months)
  • Psychological well-being (Patient Health Questionnaire, PHQ-4)(6 months)
  • Quality of life (EuroQol 5-dimension 5-level questionnaire, EQ-5D-5L)(6 months)
  • Feedback on instant message-delivered personalised lifestyle modification intervention(6 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Instant Message-delivered Personalised Lifestyle... | 临床试验